PROLX Pharmaceuticals Reports On Novel Anticancer Drug, PX-866 At International Cancer Meeting And Collaborates For Its Development With The National Cancer Institute
10/19/2005 5:08:43 PM
ProlX Pharmaceuticals Corp. announced today that CEO Dr. D. Lynn Kirkpatrick presented a proffered paper at this week's 16th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. The presentation, titled "PX-866: A novel antitumor inhibitor of PI-3-kinase" described the molecular target and antitumor activity of this promising new cancer therapy. PX-866, a PI-3-kinase inhibitor at nanomolar concentrations in vitro, has selective target inhibition in animal tumors. The agent by itself provides good antitumor control when delivered either parenterally or orally, and also enhances the activity of radiation, and cytotoxic or other molecularly targeted therapies. The combination of the PI-3-kinase inhibitor, PX-866 with other targeted therapies such as EGFR and VEGF inhibitors provides greater than additive benefit in animal studies.
comments powered by